An observational study in Skin Cancer, sponsored by Brugmann University Hospital. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by Brugmann University Hospital · Observational
Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity.
The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.
582 studies on the registry are indexed under Skin Neoplasms; 114 are open to participants now.
This study's enrollment of 373 is above the median of 200 across 134 observational studies indexed under Skin Neoplasms.
Browse Skin Neoplasms studies →Brugmann University Hospital is the lead sponsor of 116 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Identification of all patients who have undergone surgical excision of benign or malignant facial and/or eyelid tumors over the past 5 years in the Dermatology and/or Ophthalmology Departments of the CHU Saint-Pierre and CHU Brugmann hospitals.
Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.
Exclusion Criteria:
Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.
Data extraction from medical files
Age
Age of the patient at the time of diagnose
Time frame: 5 minutes
Sex
Sex of the patient
Time frame: 5 minutes
Name of the department in which the patient is followed
Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital
Time frame: 5 minutes
Tumor anatomical location
Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.
Time frame: 5 minutes
Tumor size
Tumor size in millimeters
Time frame: 5 minutes
Laterality
Laterality: left, right, median
Time frame: 5 minutes
Multiple or single tumor
Multiple or single tumor
Time frame: 5 minutes
Primitive tumor or recidive
Primitive tumor or recidive
Time frame: 5 minutes
Risk factor: phototype
Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.
Time frame: 5 minutes
Risk factor: immunosuppression (yes/no)
Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma
Time frame: 5 minutes
Risk factor: keratosis
Actinic keratosis of the face
Time frame: 5 minutes
Risk factor: solar exposition (yes/no)
Lived in a sunny European country\> 1 year, lived in a sunny country outside Europe\> 1 year, sunbed use\> 1 session, history of solar erythema during childhood.
Time frame: 5 minutes
Diagnosis
Time between the appearance of the tumor and the first consultation
Time frame: 5 minutes
Locoregional extension report (yes/no)
Locoregional extension report (yes/no)
Time frame: 5 minutes
Histological diagnosis of the tumor
Histological diagnosis of the tumor
Time frame: 5 minutes
Healthy or invaded margins
Healthy or invaded margins
Time frame: 5 minutes
Superficial or infiltrating tumor
Superficial or infiltrating tumor
Time frame: 5 minutes
Diagnostic method
Diagnostic method: curettage, punch, biopsy, flattening
Time frame: 5 minutes
Surgical management method
Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen
Time frame: 5 minutes
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brugmann University Hospital